Etelcalcetide: A Drug for Treating Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Undergoing Hemodialysis
Article Sidebar
Main Article Content
Abstract
This article reviews the information of etelcalcetide, a new calcimimetics drug, covering general information, efficacy and adverse drug reactions in order to guide the use of this drug. Elelcalcetide was registered in Thailand in 2018 for the treatment of secondary hyperparathyroidism in chronic kidney disease patients undergoing hemodialysis. The most common adverse reaction was hypocalcemia, found in approximately 64% of drug users. Therefore, initiation of the drug is not recommended when the patient has a calcium level less than 8.3 mg/dL. Calcium levels should be regularly monitored in users of this drug. Studies on the drug’s efficacy in lowering parathyroid hormone levels compared to the other calcimimetics or cinacalcet found that the effectiveness of etelcalcetide was not inferior to that of cinacalcet (P<0.001). However, the incidence of hypocalcemia with etelcalcetide was higher than that of cinacalcet (5% in patients treated with etelcalcetide and 2.3% among cinacalcet-treated patients). Switching from cinacalcet to etelcalcetide should start after stopping cinacalcet for at least 7 days to reduce the risk of hypocalcemia.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2009; 25: 1567-75.
Chuang SH, Wong HC, El AV, How PPC. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes. Singapore Med J 2016; 57: 603.
Abdu A, Abdu A, Arogundade FA. Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in Kano, Northwest Nigeria. Ann Afr Med 2019; 18: 191.
Sutheechai S, Sudchada P. Mineral and bone disorder in chronic kidney disease. Srinagarind Medical Journal 2012; 27: 415-23.
Saliba W, El-Haddad B. Secondary hyperparathy roidism: pathophysiology and treatment. J Am Board Fam Med 2009; 22: 574-81.
Vestergaard P. Medical treatment of primary, secondary, and tertiary hyperparathyroidism. Curr Drug Saf 2011; 6: 108-13.
Heath III H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980; 302: 189-93.
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 2017; 92: 26-36.
Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-83.
Eidman KE, Wetmore JB, editors. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ. Seminars in dialysis 2018; 31: 440-4.
Amgen. Parsabiv (etelcalcetide). Full prescribing information. Thousand Oaks, CA: Amgen Inc; 2017.
Wu B, Melhem M, Subramanian R, Chen P, Jaramilla SB, Fouqueray B, et al. Clinical pharma cokinetics and pharmacodynamics of etelcalcetide, a novel calcimimetic for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. J Clin Pharmacol 2018; 58: 717-26.
Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Fujii A, Yamauchi A, et al. A single-and multiple-dose, multicenter study of etelcalcetide in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int Rep 2017; 2: 634-44.
Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 2017; 317: 146-55.
Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317: 156-64.
Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant 2020; 35: 1769-78.
Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Odani M, et al. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathy roidism. Clin Exp Nephrol. 2018; 22: 426-36.
Kurokawa Y, Kaida Y, Hazama T, Nakayama Y, Otome T, Shibata R, et al. Effect of switching from cinacalcet to etelcalcetide on secondary hyperpara thyroidism in patients undergoing hemodialysis: an ESCORT trial. Renal Replacement Therapy 2020; 6: 1-10.
Fielden MR, Dean Jr C, Black K, Sawant SG, Subramanian R, Tomlinson JE, et al. Nonclinical safety profile of etelcalcetide, a novel peptide calci mimetic for the treatment of secondary hyperpara thyroidism. Int J Toxicol 2016; 35: 294-308.
Sohn W, Salusky IB, Schmitt CP, Taylan C, Walle JV, Ngang J, et al. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. Pediatr Nephrol 2021; 36: 133-42.
